NuCana (NCNA) Competitors $1.07 +0.24 (+28.92%) Closing price 03/27/2025 03:59 PM EasternExtended Trading$1.02 -0.05 (-4.21%) As of 03/27/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NCNA vs. ABVC, APLM, AIM, ONCO, DWTX, HOTH, AIMD, OBSV, ADXN, and BFRIShould you be buying NuCana stock or one of its competitors? The main competitors of NuCana include ABVC BioPharma (ABVC), Apollomics (APLM), AIM ImmunoTech (AIM), Onconetix (ONCO), Dogwood Therapeutics (DWTX), Hoth Therapeutics (HOTH), Ainos (AIMD), ObsEva (OBSV), Addex Therapeutics (ADXN), and Biofrontera (BFRI). These companies are all part of the "pharmaceutical products" industry. NuCana vs. ABVC BioPharma Apollomics AIM ImmunoTech Onconetix Dogwood Therapeutics Hoth Therapeutics Ainos ObsEva Addex Therapeutics Biofrontera ABVC BioPharma (NASDAQ:ABVC) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, community ranking, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation. Do institutionals and insiders believe in ABVC or NCNA? 11.4% of ABVC BioPharma shares are owned by institutional investors. Comparatively, 44.0% of NuCana shares are owned by institutional investors. 11.9% of ABVC BioPharma shares are owned by company insiders. Comparatively, 31.2% of NuCana shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media favor ABVC or NCNA? In the previous week, NuCana had 6 more articles in the media than ABVC BioPharma. MarketBeat recorded 8 mentions for NuCana and 2 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 1.44 beat NuCana's score of 0.92 indicating that ABVC BioPharma is being referred to more favorably in the media. Company Overall Sentiment ABVC BioPharma Positive NuCana Positive Which has preferable earnings & valuation, ABVC or NCNA? ABVC BioPharma has higher revenue and earnings than NuCana. ABVC BioPharma is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioABVC BioPharma$509.79K20.34-$10.52M-$0.86-0.93NuCanaN/AN/A-$34.37M-$6.55-0.16 Which has more risk and volatility, ABVC or NCNA? ABVC BioPharma has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, NuCana has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Is ABVC or NCNA more profitable? NuCana has a net margin of 0.00% compared to ABVC BioPharma's net margin of -1,619.65%. ABVC BioPharma's return on equity of -104.94% beat NuCana's return on equity.Company Net Margins Return on Equity Return on Assets ABVC BioPharma-1,619.65% -104.94% -56.81% NuCana N/A -314.47%-112.60% Does the MarketBeat Community believe in ABVC or NCNA? NuCana received 251 more outperform votes than ABVC BioPharma when rated by MarketBeat users. CompanyUnderperformOutperformABVC BioPharmaN/AN/ANuCanaOutperform Votes25167.65% Underperform Votes12032.35% Do analysts prefer ABVC or NCNA? NuCana has a consensus price target of $25.00, indicating a potential upside of 2,236.45%. Given NuCana's stronger consensus rating and higher possible upside, analysts plainly believe NuCana is more favorable than ABVC BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00NuCana 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryNuCana beats ABVC BioPharma on 10 of the 16 factors compared between the two stocks. Remove Ads Get NuCana News Delivered to You Automatically Sign up to receive the latest news and ratings for NCNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NCNA vs. The Competition Export to ExcelMetricNuCanaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.83M$6.91B$5.64B$8.06BDividend YieldN/A2.73%4.56%4.02%P/E Ratio-0.107.2023.1319.03Price / SalesN/A226.01383.8993.17Price / CashN/A65.6738.1634.64Price / Book0.126.476.944.33Net Income-$34.37M$141.90M$3.20B$247.06M7 Day Performance32.59%-3.05%-2.30%-0.52%1 Month Performance15.28%-4.63%3.10%-3.73%1 Year Performance-86.30%-8.61%11.22%1.74% NuCana Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NCNANuCana3.8172 of 5 stars$1.07+28.9%$25.00+2,236.4%-86.3%$2.83MN/A-0.1030Short Interest ↓Gap UpABVCABVC BioPharma1.4212 of 5 stars$0.65+0.7%N/A-33.4%$8.44M$509,788.00-0.7630Upcoming EarningsShort Interest ↓Positive NewsGap UpAPLMApollomics2.5969 of 5 stars$7.64-0.7%$200.00+2,519.5%-86.1%$8.30M$1.22M0.0045Short Interest ↓News CoveragePositive NewsGap UpAIMAIM ImmunoTech1.6676 of 5 stars$0.12+3.4%$2.75+2,191.7%-71.1%$8.25M$190,000.00-0.2620News CoverageGap UpONCOOnconetix0.5921 of 5 stars$0.13-1.6%N/A-98.4%$8.13M$1.87M0.0012Short Interest ↑Positive NewsGap DownDWTXDogwood TherapeuticsN/A$6.09-0.5%N/AN/A$8.11MN/A-0.935HOTHHoth Therapeutics2.7283 of 5 stars$1.17+5.4%$4.00+241.9%-27.5%$8.08MN/A-0.894Short Interest ↑AIMDAinos0.4882 of 5 stars$0.52+0.2%N/A-55.9%$8.06M$20,729.00-0.3240Short Interest ↑Gap UpOBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150ADXNAddex Therapeutics2.8135 of 5 stars$7.46-1.1%$30.00+302.1%-38.4%$7.91M$556,045.00-21.9430Short Interest ↓Positive NewsBFRIBiofrontera2.3262 of 5 stars$1.01+9.1%$7.00+593.1%-26.3%$7.83M$35.36M-0.4570Short Interest ↑ Remove Ads Related Companies and Tools Related Companies ABVC BioPharma Competitors Apollomics Competitors AIM ImmunoTech Competitors Onconetix Competitors Dogwood Therapeutics Competitors Hoth Therapeutics Competitors Ainos Competitors ObsEva Competitors Addex Therapeutics Competitors Biofrontera Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NCNA) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NuCana plc Please log in to your account or sign up in order to add this asset to your watchlist. Share NuCana With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NCNA Stock Free NCNA Stock Alerts